Open house contracts for various active ingredients until 30.11.2024 or until 29.02.2024.
Abatacept, ATC-Code: L04AA24The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Guselkumab, ATC-Code: L04AC16The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Indacaterol + Glycopyrronium, ATC-Code: R03AL04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Mesalazin, ATC-Code: A07EC02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Paliperidon, ATC-Code: N05AX13The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Palivizumab, ATC-Code: J06BB16The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Permethrin, ATC-Code: P03AC04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Raltegravir, ATC-Code: J05AX08The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Tolvaptan, ATC-Code: C03XA01, G04BX21The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Tranexamsäure, ATC-Code: B02AA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Triptorelin, ATC-Code: H01CA07The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Adalimumab, ATC-Code: L04AB04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest start of the contract is 01.01.2023, the end of the contract is 29.02.2024. It is possible to join this open house procedure at any time within the term of the contract.
Triptorelin, ATC-Code: L02AE04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Valsartan, ATC-Code: C09CA03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Budesonid, ATC-Code: A07EA06The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Clonidin, ATC-Code: C02AC01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Clonidin, ATC-Code: S01EA04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Erythropoetin (Epoetin alfa), ATC-Code: B03XA01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Filgrastim, ATC-Code: L03AA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Follitropin Alfa, ATC code: G03GA05The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.
Follitropin beta, ATC code: G03GA06The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount contract according to § 130a Abs. 8 SGB V offered for the mentioned active ingredient. The earliest contract start is 01.12.2022, contract end is 30.11.2024. It is possible to join this open house procedure at any time within the term of the contract.